العنوان: تغيير كلمة للعلاج إلى للاستخدام-

-The protocol was reviewed by scientific reviewing committee: It is written: No, the head of pharmaceutics department

There is no department having this name in the NRC

-Fund amount not specified
- It is written that Cryptosporidium oocysts will be orally inoculated to the infected groups at a dose of 2 × 103 oocysts/mouse using gastric tube, via 25-gauge needle tipped with plastic tubing. From where will the authors get cryptosporidium oocysts?
- It is written that the fourth and fifth groups will be infected treated mice with artemisia annua of high dose (30 mg/kg), and low dose (15 mg/kg) respectively, daily for 5 consecutive days.  In another part it is written that group 4 and five treated with high and low dose of artemesia annua chitosan nanoparticles. So, group 4 & 5 will receive the extract or the nanoparticles? The crude extract must be compared to the extract-loaded nanoparticles as well as unmedicated nanoparticles.  
-What are the precautions followed to prevent transmission of the infection in the lab or animal house? As transmission risk is high by ingestion or inhalation (lower risk).
-Where the microscopic examination of the faeces samples for counting number of Cryptosporidium oocysts will be done?
 
- If more than one method is used per species please list all methods: Exsanguination is written, while blood samples withdrawing is not mentioned.
 
نموذج 90 للتقدم للجنة هو الإصدار القديم وهو غير سارى حالياً
 
Endorsement letter for researchers dealing with animal is not clear, a higher resolution version is preferred.